The objective of this paper is to identify the prevalence, risk factors, and impact on mortality of neuropsychiatric systemic lupus erythematosus (NPSLE).
Methods
Patients from the Hanyang BAE lupus cohort were registered and followed from 1998 to 2015. NPSLE was defined using American College of Rheumatology (ACR) case definitions and Ainiala criteria. Demographics, autoantibodies, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and Systemic Lupus International Collaborating Clinic (SLICC)/ACR Damage Index were collected at baseline and then annually. Mortality data were derived by linking data from the Korean National Statistics Office. Multivariable logistic regression and Cox regression analysis were conducted in the inception cohort to assess the risk factors and mortality impact of NPSLE.
Results
Of 1121 registered patients, 429 (38.3%) had NPSLE manifestations according to ACR criteria and 216 (19.3%) by Ainiala criteria. In multivariable logistic regression analysis, higher SLEDAI (OR 1.08, CI 1.01–1.16, p = 0.02) and antiphospholipid antibody positivity (OR 1.72, CI 1.03–2.87, p = 0.04) at SLE diagnosis increased NPSLE risk, while elevated anti-dsDNA antibodies (OR 0.43, CI 0.24–0.78, p < 0.01) and greater education duration (OR 0.92, CI 0.85–1.00, p = 0.04) showed reduced risk of NPSLE. Cox proportional hazard models demonstrated that presence of NPSLE had a three-fold increased risk of mortality (HR 3.09, CI 1.03–9.21, p = 0.04), especially in patients with focal CNS NPSLE (HR = 7.83, CI 2.12–28.96, p < 0.01).
Conclusion
Higher SLEDAI, antiphospholipid antibody positivity, absence of anti-dsDNA antibody at SLE diagnosis, and fewer years of education are risk factors for development of NPSLE. Presence of NPSLE, especially focal CNS NPSLE, increased the risk of mortality in SLE patients.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
2.
MokCCLauCSWongRW. Neuropsychiatric manifestations and their clinical associations in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol2001; 28: 766–771.
3.
VyasSHidalgoGBaqiNVon GizykiHSinghA. Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr Nephrol2002; 17: 45–49.
SannaGBertolacciniMLCuadradoMJet al.Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. J Rheumatol2003; 30: 985–992.
6.
HanlyJGMcCurdyGFougereLDouglasJAThompsonK. Neuropsychiatric events in systemic lupus erythematosus: Attribution and clinical significance. J Rheumatol2004; 31: 2156–2162.
7.
HarelLSandborgCLeeTvon SchevenE. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol2006; 33: 1873–1877.
8.
MokCCToCHMakA. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore)2006; 85: 221–228.
9.
RobertMSunithaRThulaseedharanNK. Neuropsychiatric manifestations systemic lupus erythematosus: A study from South India. Neurol India2006; 54: 75–77.
10.
YuHHLeeJHWangLCYangYHChiangBL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: A 20-year study. Lupus2006; 15: 651–657.
11.
ZhouHQZhangFCTianXPet al.Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus2008; 17: 93–99.
12.
Abdul-SattarABGodaTNegmMG. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study. Int J Rheum Dis2013; 16: 715–723.
13.
PradhanVPatwardhanMRajadhyakshaADhawaleNGhoshK. Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India. Rheumatol Int2015; 35: 541–545.
14.
HajighaemiFEtemadifarMBonakdarZS. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: A study from Iran. Adv Biomed Res2016; 5: 43–43.
15.
JönsenABengtssonAANivedORybergBSturfeltG. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology (Oxford)2002; 41: 1308–1312.
16.
SchenattoCBXavierRMBredemeierMet al.Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis2006; 65: 829–831.
17.
HanlyJGUrowitzMBSanchez-GuerreroJet al.Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum2007; 56: 265–273.
18.
Abdel-NasserAMGhalebRMMahmoudJAKhairyWMahmoudRM. Association of anti – ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol2008; 27: 1377–1385.
19.
HanlyJGSuLFarewellVMcCurdyGFougereLThompsonK. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol2009; 36: 1449–1459.
20.
SinghSGuptaMKAhluwaliaJSinghPMalhiP. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int2009; 29: 1455–1461.
21.
ChiewthanakulPSawanyawisuthKFoocharoenCTiamkaoS. Clinical features and predictive factors in neuropsychiatric lupus. Asian Pac J Allergy Immunol2012; 30: 55–60.
22.
AinialaHLoukkolaJPeltolaJKorpelaMHietaharjuA. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology2001; 57: 496–500.
23.
MorrisonECarpentierSShawEDoucetteSHanlyJG. Neuropsychiatric systemic lupus erythematosus: Association with global disease activity. Lupus2014; 23: 370–377.
24.
BortoluzziAPadovanMFarinaIGaluppiEDe LeonardisFGovoniM. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: Experience from a tertiary referral centre. Reumatismo2012; 64: 350–359.
25.
GovoniMBombardieriSBortoluzziAet al.Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: Does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford)2012; 51: 157–168.
26.
JooYBParkSYWonSBaeSC. Differences in clinical features and mortality between childhood-onset and adult-onset systemic lupus erythematosus: A prospective single-center study. J Rheumatol2016; 43: 1490–1497.
27.
JooYBBaeSC. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: Comparison with other Asian populations. Int J Rheum Dis2015; 18: 117–128.
28.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
GladmanDGinzlerEGoldsmithCet al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
31.
AinialaHHietaharjuALoukkolaJet al.Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: A population-based evaluation. Arthritis Rheum2001; 45: 419–423.
32.
BortoluzziAScirèCABombardieriSet al.Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford)2015; 54: 891–898.
33.
HanlyJGUrowitzMBSuLet al.Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis2010; 69: 529–535.
34.
HanlyJGUrowitzMBO’KeeffeAGet al.Headache in systemic lupus erythematosus: Results from a prospective, international inception cohort study. Arthritis Rheum2013; 65: 2887–2897.
35.
Magro-ChecaCZirkzeeEJBeaart-van de VoordeLJJet al.Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: Prospective data from the Leiden NPSLE cohort. Rheumatology (Oxford)2017; 56: 1676–1683.
36.
BortoluzziAFanouriakisAAppenzellerSet al.Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: A retrospective multicentre international diagnostic cohort study. BMJ Open2017; 7: e015546–e015546.
37.
TaySHMakA. Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus: Time to untie the Gordian knot?Rheumatology (Oxford)2017; 56(Suppl 1): i14–i23.
38.
WangJZhaoYZhangJLeiHZhuGFuB. Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection. Cell Biochem Biophys2014; 70: 1005–1009.
39.
ArinumaYYanagidaTHirohataS. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum2008; 58: 11301135.
40.
HusebyeESSthoegerZMDayanMet al.Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis2005; 64: 1210–1213.
41.
DeGiorgioLAKonstantinovKNLeeSCHardinJAVolpeBTDiamondB. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med2001; 7: 1189–1193.
42.
Fragoso-LoyoHCabiedesJOrozco-NarváezAet al.Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One2008; 3: e3347–e3347.
43.
Moraes-FontesMFLúcioISantosCCamposMMRisoNVaz RiscadoM. Neuropsychiatric features of a cohort of patients with systemic lupus erythematosus. ISRN Rheumatol2012; 2012: 989218–989218.
ChanLHuCJFanYCet al.Incidence of poststroke seizures: A meta-analysis. J Clin Neurosci2018; 47: 347–351.
46.
PezziniAGrassiMDel ZottoEet al.Complications of acute stroke and the occurrence of early seizures. Cerebrovasc Dis2013; 35: 444–450.
47.
ProcacciantiGZaniboniARondelliFCrisciMSacquegnaT. Seizures in acute stroke: Incidence, risk factors and prognosis. Neuroepidemiology2012; 39: 45–50.
48.
QinPXuHLaursenTMVestergaardMMortensenPB. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: Population based cohort study. BMJ2005; 331: 23–23.
ShimJSSungYKJooYBLeeHSBaeSC. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int2014; 34: 909–917.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
